Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 4/20 | 0.36 |
| ▸ | RORA | P35398 | 4/20 | 0.36 |
| ▸ | RORC | P51449 | 4/20 | 0.36 |
| ▸ | RORB | Q92753 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12759585 | 0.79 | RORA (0.32) | PGRRORARORCRORB | |
| SCHEMBL861330 | 0.77 | HSD17B10 (0.47) | PTAFRHSD17B10ALDH1A1HPGDADORA2A | |
| SCHEMBL861337 | 0.77 | PGR (0.40) | PGRRORARORCRORBHSD17B10 | |
| SCHEMBL861753 | 0.74 | KDM4E (0.37) | PGRRORARORCRORBHSD17B10 | |
| SCHEMBL861579 | 0.72 | PGR (0.33) | PGRRORARORCRORBHSD17B10 | |
| SCHEMBL9968160 | 0.70 | GPR3 (0.53) | PGRRORARORCRORBHSD17B10 | |
| SCHEMBL861304 | 0.70 | PGR (0.32) | PGRRORARORCRORBMEN1 | |
| SCHEMBL20313295 | 0.70 | MEN1 (0.39) | PTAFRPGRRORARORCRORB | |
| SCHEMBL841591 | 0.69 | PGR (0.33) | PGRRORARORCRORB | |
| SCHEMBL25725654 | 0.69 | MAPT (0.41) | PGRRORARORCRORBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150311455-A1 | Method Of Forming Metal Complex Compound, And Organic Electroluminescence Device | UDC IRELAND LTD (IE) | 2015-10-29 | — | — | US | disclosed |
| US-20150311455-A1 | Method Of Forming Metal Complex Compound, And Organic Electroluminescence Device | UDC IRELAND LTD (IE) | 2015-10-29 | — | — | US | disclosed |
| US-9062084-B2 | Method of forming metal complex compound, and organic electroluminescence device | UDC Ireland (IE) | 2015-06-23 | — | — | US | disclosed |
| US-9062084-B2 | Method of forming metal complex compound, and organic electroluminescence device | UDC Ireland (IE) | 2015-06-23 | — | — | US | disclosed |
| US-8142909-B2 | Blue phosphorescent imidazophenanthridine materials | UNIVERSAL DISPLAY CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8142909-B2 | Blue phosphorescent imidazophenanthridine materials | UNIVERSAL DISPLAY CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110050093-A1 | METHOD OF FORMING METAL COMPLEX COMPOUND, AND ORGANIC ELECTROLUMINESCENCE DEVICE | FUJIFILM CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110050093-A1 | METHOD OF FORMING METAL COMPLEX COMPOUND, AND ORGANIC ELECTROLUMINESCENCE DEVICE | FUJIFILM CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| WO-2008156879-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION | 2008-12-04 | — | — | US | disclosed |
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110050093-A1 | METHOD OF FORMING METAL COMPLEX COMPOUND, AND ORGANIC ELECTROLUMINESCENCE DEVICE | ZFR, PORCN, OR10J3 | PTAFR 3821/4885PGR 3202/4885RORA 2945/4885 |
| US-20150311455-A1 | Method Of Forming Metal Complex Compound, And Organic Electroluminescence Device | ZFR, PORCN, OR10J3 | PTAFR 3821/4885PGR 3202/4885RORA 2945/4885 |
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | IK, CRY1, MAP1LC3C | PTAFR 2151/4885PGR 3621/4885RORA 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.